Business
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
DUBLIN, Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"DUBLIN, Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.\n\n \n \n \n \n \n \n\n \nRick Winningham, CEO, will participate in a Fireside Chat on Tuesday, September 9 at 1:30 PM EDT (10:30 AM PDT / 6:30 PM IST).\nManagement will be hosting in-person meetings during the event. Interested investors should contact their H.C. Wainwright representative to request a meeting.\nA live webcast of the event may be accessed here or on the \"Events and Presentation\" page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.\nAbout Theravance Biopharma \nTheravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.\nFor more information, please visit www.theravance.com.THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).\nYUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.\nContact:[email protected]\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543498.html\nSOURCE Theravance Biopharma, Inc.","length":4608,"tagName":"div"}]